Titre : Inhibiteurs d'activateurs du plasminogène

Inhibiteurs d'activateurs du plasminogène : Questions médicales fréquentes

Termes MeSH sélectionnés :

Models, Structural
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs d'activateurs du plasminogène : Questions médicales les plus fréquentes", "headline": "Inhibiteurs d'activateurs du plasminogène : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteurs d'activateurs du plasminogène : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-30", "dateModified": "2025-03-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteurs d'activateurs du plasminogène" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs de la coagulation sanguine", "url": "https://questionsmedicales.fr/mesh/D001779", "about": { "@type": "MedicalCondition", "name": "Facteurs de la coagulation sanguine", "code": { "@type": "MedicalCode", "code": "D001779", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.119" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteur-1 d'activateur du plasminogène", "alternateName": "Plasminogen Activator Inhibitor 1", "url": "https://questionsmedicales.fr/mesh/D017395", "about": { "@type": "MedicalCondition", "name": "Inhibiteur-1 d'activateur du plasminogène", "code": { "@type": "MedicalCode", "code": "D017395", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.119.832.500" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteur-2 d'activateur du plasminogène", "alternateName": "Plasminogen Activator Inhibitor 2", "url": "https://questionsmedicales.fr/mesh/D017396", "about": { "@type": "MedicalCondition", "name": "Inhibiteur-2 d'activateur du plasminogène", "code": { "@type": "MedicalCode", "code": "D017396", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.119.832.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Inhibiteurs d'activateurs du plasminogène", "alternateName": "Plasminogen Inactivators", "code": { "@type": "MedicalCode", "code": "D015849", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Robert J Parmer", "url": "https://questionsmedicales.fr/author/Robert%20J%20Parmer", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Veterans Administration San Diego Healthcare System, University of California, San Diego, San Diego, CA, United States." } }, { "@type": "Person", "name": "Lindsey A Miles", "url": "https://questionsmedicales.fr/author/Lindsey%20A%20Miles", "affiliation": { "@type": "Organization", "name": "Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, United States." } }, { "@type": "Person", "name": "Nagyung Baik", "url": "https://questionsmedicales.fr/author/Nagyung%20Baik", "affiliation": { "@type": "Organization", "name": "Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, United States." } }, { "@type": "Person", "name": "Beate Heissig", "url": "https://questionsmedicales.fr/author/Beate%20Heissig", "affiliation": { "@type": "Organization", "name": "Immunological Diagnosis, Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan." } }, { "@type": "Person", "name": "Koichi Hattori", "url": "https://questionsmedicales.fr/author/Koichi%20Hattori", "affiliation": { "@type": "Organization", "name": "Center for Genomic & Regenerative Medicine, Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "How does manufacturing haze pollution decrease in China: a decomposition study of structural model based on general equilibrium framework.", "datePublished": "2022-12-15", "url": "https://questionsmedicales.fr/article/36517609", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11356-022-24699-7" } }, { "@type": "ScholarlyArticle", "name": "Structural Model of the Human BTG2-PABPC1 Complex by Combining Mutagenesis, NMR Chemical Shift Perturbation Data and Molecular Docking.", "datePublished": "2022-05-28", "url": "https://questionsmedicales.fr/article/35640718", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jmb.2022.167662" } }, { "@type": "ScholarlyArticle", "name": "Childhood stunting and subsequent educational outcomes: a marginal structural model analysis from a South African longitudinal study.", "datePublished": "2022-08-26", "url": "https://questionsmedicales.fr/article/36008100", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1017/S1368980022001823" } }, { "@type": "ScholarlyArticle", "name": "Causal inference in survival analysis using longitudinal observational data: Sequential trials and marginal structural models.", "datePublished": "2023-04-22", "url": "https://questionsmedicales.fr/article/37086186", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/sim.9718" } }, { "@type": "ScholarlyArticle", "name": "A morphological, topological and mechanical investigation of gyroid, spinodoid and dual-lattice algorithms as structural models of trabecular bone.", "datePublished": "2022-11-18", "url": "https://questionsmedicales.fr/article/36436405", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jmbbm.2022.105584" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Facteurs de la coagulation sanguine", "item": "https://questionsmedicales.fr/mesh/D001779" }, { "@type": "ListItem", "position": 4, "name": "Inhibiteurs d'activateurs du plasminogène", "item": "https://questionsmedicales.fr/mesh/D015849" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteurs d'activateurs du plasminogène - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteurs d'activateurs du plasminogène", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteurs d'activateurs du plasminogène", "description": "Comment diagnostiquer une thrombose ?\nQuels tests pour évaluer l'activité plasminogène ?\nQuels signes indiquent une embolie pulmonaire ?\nComment évaluer le risque de saignement ?\nQuels examens pour une thrombose veineuse profonde ?", "url": "https://questionsmedicales.fr/mesh/D015849?mesh_terms=Models,+Structural&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteurs d'activateurs du plasminogène", "description": "Quels sont les symptômes d'une thrombose ?\nComment reconnaître une crise d'angine ?\nQuels signes d'une embolie cérébrale ?\nQuels symptômes d'une hémorragie interne ?\nComment se manifeste une thrombose artérielle ?", "url": "https://questionsmedicales.fr/mesh/D015849?mesh_terms=Models,+Structural&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteurs d'activateurs du plasminogène", "description": "Comment prévenir les thromboses ?\nQuels conseils pour les voyages longs ?\nComment réduire le risque post-chirurgical ?\nQuels aliments éviter pour prévenir les caillots ?\nComment le tabagisme influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D015849?mesh_terms=Models,+Structural&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteurs d'activateurs du plasminogène", "description": "Quels traitements pour une thrombose ?\nComment agissent les inhibiteurs d'activateurs ?\nQuand utiliser des thrombolytiques ?\nQuels sont les effets secondaires des anticoagulants ?\nComment surveiller l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D015849?mesh_terms=Models,+Structural&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteurs d'activateurs du plasminogène", "description": "Quelles sont les complications d'une thrombose ?\nQuels risques d'hémorragie avec les traitements ?\nComment une embolie peut-elle affecter la santé ?\nQuels effets à long terme d'une thrombose ?\nComment prévenir les complications post-thrombose ?", "url": "https://questionsmedicales.fr/mesh/D015849?mesh_terms=Models,+Structural&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteurs d'activateurs du plasminogène", "description": "Quels sont les facteurs de risque de thrombose ?\nComment l'âge influence-t-il le risque ?\nQuel rôle joue la génétique dans la thrombose ?\nComment les contraceptifs influencent-ils le risque ?\nQuel impact a l'hypertension sur le risque ?", "url": "https://questionsmedicales.fr/mesh/D015849?mesh_terms=Models,+Structural&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une thrombose ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic de thrombose se fait par échographie, tests sanguins et évaluation clinique." } }, { "@type": "Question", "name": "Quels tests pour évaluer l'activité plasminogène ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests comme le dosage du plasminogène et l'activité des activateurs sont utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent une embolie pulmonaire ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent douleur thoracique, essoufflement et toux avec sang." } }, { "@type": "Question", "name": "Comment évaluer le risque de saignement ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par l'historique médical, les antécédents de saignement et des tests." } }, { "@type": "Question", "name": "Quels examens pour une thrombose veineuse profonde ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie Doppler est l'examen de choix pour diagnostiquer une TVP." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une thrombose ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur, gonflement et rougeur dans la zone affectée." } }, { "@type": "Question", "name": "Comment reconnaître une crise d'angine ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une crise d'angine se manifeste par une douleur thoracique, souvent irradiant vers le bras." } }, { "@type": "Question", "name": "Quels signes d'une embolie cérébrale ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des troubles de la parole, faiblesse d'un côté et confusion." } }, { "@type": "Question", "name": "Quels symptômes d'une hémorragie interne ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure douleur abdominale, faiblesse et pâleur." } }, { "@type": "Question", "name": "Comment se manifeste une thrombose artérielle ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle se manifeste par une douleur intense, une pâleur et une perte de pouls dans le membre." } }, { "@type": "Question", "name": "Comment prévenir les thromboses ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut l'exercice régulier, l'hydratation et l'évitement de la sédentarité." } }, { "@type": "Question", "name": "Quels conseils pour les voyages longs ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de se lever régulièrement, s'hydrater et porter des bas de compression." } }, { "@type": "Question", "name": "Comment réduire le risque post-chirurgical ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation d'anticoagulants et de dispositifs de compression aide à réduire le risque." } }, { "@type": "Question", "name": "Quels aliments éviter pour prévenir les caillots ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Évitez les aliments riches en vitamine K, qui peuvent interférer avec les anticoagulants." } }, { "@type": "Question", "name": "Comment le tabagisme influence-t-il le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme augmente le risque de thrombose en favorisant l'agrégation plaquettaire." } }, { "@type": "Question", "name": "Quels traitements pour une thrombose ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les anticoagulants, les thrombolytiques et la compression." } }, { "@type": "Question", "name": "Comment agissent les inhibiteurs d'activateurs ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils bloquent l'activation du plasminogène, réduisant la dégradation des caillots." } }, { "@type": "Question", "name": "Quand utiliser des thrombolytiques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont utilisés en cas de thrombose aiguë pour dissoudre rapidement les caillots." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des anticoagulants ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent saignements, ecchymoses et interactions médicamenteuses." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La surveillance se fait par des tests sanguins réguliers pour évaluer la coagulation." } }, { "@type": "Question", "name": "Quelles sont les complications d'une thrombose ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'embolie pulmonaire, l'insuffisance veineuse et les ulcères." } }, { "@type": "Question", "name": "Quels risques d'hémorragie avec les traitements ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements anticoagulants augmentent le risque d'hémorragie, nécessitant une surveillance." } }, { "@type": "Question", "name": "Comment une embolie peut-elle affecter la santé ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une embolie peut entraîner des lésions organiques, des douleurs thoraciques et des décès." } }, { "@type": "Question", "name": "Quels effets à long terme d'une thrombose ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des douleurs chroniques et des problèmes circulatoires." } }, { "@type": "Question", "name": "Comment prévenir les complications post-thrombose ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La rééducation, l'exercice et le suivi médical régulier aident à prévenir les complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de thrombose ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'obésité, le tabagisme, l'immobilisation et les antécédents familiaux." } }, { "@type": "Question", "name": "Comment l'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Le risque de thrombose augmente avec l'âge en raison de la diminution de la circulation sanguine." } }, { "@type": "Question", "name": "Quel rôle joue la génétique dans la thrombose ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des mutations génétiques peuvent prédisposer à des troubles de la coagulation et à la thrombose." } }, { "@type": "Question", "name": "Comment les contraceptifs influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Les contraceptifs hormonaux peuvent augmenter le risque de thrombose, surtout chez les fumeuses." } }, { "@type": "Question", "name": "Quel impact a l'hypertension sur le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension peut endommager les vaisseaux sanguins, augmentant le risque de thrombose." } } ] } ] }

Sources (10000 au total)

Childhood stunting and subsequent educational outcomes: a marginal structural model analysis from a South African longitudinal study.

To examine the association between childhood stunting and grade completion (as educational outcome) in South Africa.... Longitudinal study. Data were obtained using the National Income Dynamics Study over five waves (2008 to 2017). Children were tracked at wave 1 in 2008 until wave 5 in 2017 to determine their total ye... Nationally representative study of South African households.... A total of 2629 children aged 2 and 3 years in 2008.... We observed a substantial decrease in the prevalence of stunting between wave 1 (28·2 %) and wave 4 (8·6 %). Our marginal structural model results suggest that childhood stunting was significantly ass... These findings underscore the fact that stunting is a significant predictor of academic achievement, whose effects might be long-lasting....

An integrated method for studying the biodegradation of benzo[a]pyrene by Citrobacter sp. HJS-1 and interaction mechanism based on the structural model of the initial dioxygenase.

A bacterial strain Citrobacter sp. HJS-1 was discovered from the sludge in a drainage canal of a coal mine. Firstly, its biodegradation capacity for benzo[a]pyrene (BaP) was detected under different c...

Structural model of the relationship between physical activity and students' quality of life: Mediating role of body mass index and moderating role of gender.

As a country's future leaders and pioneers, University students must live with healthy habits. In order to achieve a healthy lifestyle, Physical activity and Quality of Life can serve as suitable indi... The research was a cross-sectional study. The number of participants was 225 students of the University. The participants answered three questionnaires, including Demographic, International Physical A... PA (r = -0.726, P<0.001) and QOL (r = -0.405, P<0.001) have significantly inverse relationship with BMI, whereas the QOL and PA were proven to be positively related (r = 0.357, P<0.001). Moreover, the... Study findings supported the research hypothesis. Gender exhibited moderating role in the relationship between PA and QOL, considering the mediating role of BMI....

A thrombophilic allele of clotting Factor VII/VIIa promoting recurrent pulmonary emboli, clinical details, and a structural model of the altered protein: a case report.

The clotting or hemostasis system is a meticulously regulated set of enzymatic reactions that occur in the blood and culminate in formation of a fibrin clot. The precisely calibrated signaling system ... The 52-year-old patient, with European, Cherokee and African American origins, FS was identified as having low FVII (10%) prior to elective surgery for an umbilical hernia. He was given low doses of N... FS has a congenitally mutated FVII/FVIIa gene, which carries a R315W missense mutation in one allele and a mutated start codon (ATG to ACG) in the other allele, thus rendering the patient effectively ... Factor VII can be considered the gatekeeper of the coagulation system. Here we describe an inherited mutation in which the gatekeeper function is altered. Instead of the expected bleeding manifestatio...

Virtual Quasi-2D Intermediates as Building Blocks for Plausible Structural Models of Amyloid Fibrils from Proteins with Complex Topologies: A Case Study of Insulin.

Conformational transitions of globular proteins into amyloid fibrils are complex multistage processes exceedingly challenging to simulate using molecular dynamics (MD). Slow monomer diffusion rates an...